Safety & Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in

Updated 06/21/2024

Status Completed

Clinical Trial Summary

This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02505776
Study type	Observational
Source	Allergan
Contact
Status	Completed
Phase
Start date	December 8, 2014
Completion date	May 21, 2018

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01229423` - Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects	Phase 4
	Completed	`NCT01623479` - An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
	Completed	`NCT01064882` - Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence	Phase 2
	Completed	`NCT01023841` - Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children	Phase 4
	Completed	`NCT01391286` - Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis	Phase 3
	Completed	`NCT01391273` - Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis	Phase 3